Human Platelet Antigen (HPA) testing of donors and patients enables accurate identification of platelet antigen incompatibilities that may contribute to conditions such as fetal/neonatal alloimmune thrombocytopenia (FNAIT), post‑transfusion purpura (PTP), or platelet transfusion refractoriness. Our HPA genotyping delivers high‑resolution results that help clinicians better predict and prevent immune‑mediated platelet complications.
When Is HPA Genotyping Useful?
Human Platelet Antigen (HPA) genotyping is a molecular test used to determine a patient’s or donor’s platelet antigen profile, including HPA-1a status and other clinically significant HPA types. This testing plays a critical role in the investigation of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and platelet transfusion support for alloimmunized patients.
HPA genotyping is commonly used in the following clinical and donor scenarios:
Investigation of FNAIT
- Determining maternal, paternal, or neonatal HPA type
- Supporting the identification of platelet-specific alloantibodies
Evaluation of platelet alloantibodies
- Results integrated with platelet antibody screening and crossmatch testing
Platelet transfusion refractoriness
- Assisting in the selection of HPA-compatible platelet products
Donor testing
- Identifying HPA-negative donors for patients with known platelet alloantibodies
- Supporting future transfusion needs by expanding typed donor inventories